Vivos Therapeutics (VVOS) Net Cash Flow Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -54.17% |
| 10 | Vivos Therapeutics | 4.95 Mn | 3.15 Mn | 2.95 Mn | 95.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.32% |
| Dec 31, 2025 | -1,581.67% |
| Sep 30, 2025 | -143.53% |
| Jun 30, 2025 | -321.01% |
| Mar 31, 2025 | -505.17% |
| Dec 31, 2024 | -108.56% |
| Sep 30, 2024 | 81.18% |
| Jun 30, 2024 | 237.11% |
| Mar 31, 2024 | -72.55% |
| Dec 31, 2023 | 121.82% |
| Sep 30, 2023 | 50.29% |
| Jun 30, 2023 | 39.93% |
| Mar 31, 2023 | 156.87% |
| Dec 31, 2022 | 28.66% |
| Sep 30, 2022 | -5.75% |
| Jun 30, 2022 | -125.71% |
| Mar 31, 2022 | -49.52% |
| Dec 31, 2021 | -127.04% |
| Sep 30, 2021 | -594.41% |
| Jun 30, 2021 | 6,448.46% |